A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1059 participants.

Also called NCT05205499

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,059 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05205499
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05205499. Allocation not applicable; no masking; primary purpose treatment. Start 2022-03-10 (actual); primary completion 2024-07-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease
Acronym
IRONMAN-III
Intervention (Device)
Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
Lead sponsor
Biotyx Medical (Shenzhen) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05205499
Content hash
7edb5cfdf7bb7b6b18dfe7f6e25df247ffdf31e291b7781b4231c8e5e70fcd6f